AAV OPTIRPE65
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leber Congenital Amaurosis (LCA)
Conditions
Leber Congenital Amaurosis (LCA), Eye Diseases, Eye Diseases, Hereditary, Retinal Diseases
Trial Timeline
Nov 1, 2016 → Jul 1, 2023
NCT ID
NCT02946879About AAV OPTIRPE65
AAV OPTIRPE65 is a pre-clinical stage product being developed by MeiraGTx for Leber Congenital Amaurosis (LCA). The current trial status is completed. This product is registered under clinical trial identifier NCT02946879. Target conditions include Leber Congenital Amaurosis (LCA), Eye Diseases, Eye Diseases, Hereditary.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02946879 | Pre-clinical | Completed |
Competing Products
12 competing products in Leber Congenital Amaurosis (LCA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EDIT-101 | Editas Medicine | Phase 1/2 | 33 |
| AAV RPE65 | MeiraGTx | Phase 1/2 | 33 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 2 | 44 |
| Idebenone | Santhera Pharmaceuticals | Approved | 77 |
| Idebenone 150 MG Oral Tablet | Santhera Pharmaceuticals | Pre-clinical | 15 |
| Idebenone | Santhera Pharmaceuticals | Pre-clinical | 15 |
| sepofarsen | ProQR | Phase 2/3 | 57 |
| sepofarsen | ProQR | Phase 2/3 | 57 |
| Idebenone + Placebo | Santhera Pharmaceuticals | Phase 3 | 69 |
| GS010 | GenSight Biologics | Phase 3 | 69 |
| GS010 | GenSight Biologics | Phase 3 | 69 |
| Placebo | GenSight Biologics | Phase 3 | 69 |
Other Products from MeiraGTx
AAV RPE65Phase 1/2
33
AAV - CNGB3Phase 1/2
33
adeno-associated virus vector AAV- CNGA3Phase 1/2
33
AAV2hAQP1Phase 1
25
AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands)Phase 1
25